1 4 naphthoquinone/悪性腫瘍

FIELD OF THE INVENTION The present invention is directed to novel 4-substituted-1,2-naphthoquinones and the use of 4-substituted-1,2-naphthoquinones in the inhibition of neoplastic cell growth. DESCRIPTION OF THE PRIOR ART 1,2-naphthoquinones (also known as ortho-naphthoquinones, and referred to

FIELD OF THE INVENTION The present invention is directed to novel 4-substituted-1,2-naphthoquinones and the use of 4-substituted-1,2-naphthoquinones in the inhibition of neoplastic cell growth. DESCRIPTION OF THE PRIOR ART 1,2-naphthoquinones (also known as ortho-naphthoquinones, and referred to

This application is a 371 of PCT/9B93/01669 filed Aug. 6, 1993. The present invention relates to the treatment of cancer. More particularly, the invention is concerned with the use of 2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone and physiologically acceptable salts and

BACKGROUND OF THE INVENTION 1. Field of Invention This invention in the field of biochemistry and medicine is directed to the prevention and treatment of human cancer by administration of a combination of magnesium ascorbate (magnesium Vitamin C or "MgVC.sub.2") and the naphthoquinone Vitamin K3

FIELD OF THE INVENTION The invention in the field of biochemistry and medicine relates to combination therapy of cancer using compounds of the hydroxytolan (HT) family in combination with ascorbate and naphthoquinone (Vitamin K.sub.3 or "VK.sub.3") or a quinone or semiquinone analogue of

FIELD OF THE INVENTION The present invention relates to 2,3-disubstituted naphthoquinone compounds and the use of such compounds as antitumor agents. REFERENCES Ambrogi, V., et al., Br. J. Pharm. 40:871 (1970). Boyd, M., in CANCER; PRINCIPLES AND PRACTICE OF ONCOLOGY UPDATES (De Vita, V. T., et al.,

STATEMENT OF RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH Not applicable TECHNICAL FIELD This invention relates to therapeutic compositions in which a cytostatic or cytocidal compound, such as a polyamine analog or a quinone, is conjugated to a polypeptide recognized and cleaved by

STATEMENT OF RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH Not applicable TECHNICAL FIELD This invention relates to therapeutic compositions in which a cytostatic or cytocidal compound, such as a polyamine analog or a quinone, is conjugated to a polypeptide recognized and cleaved by

BACKGROUND OF THE INVENTION 1. Field of the Invention This invention relates to compounds having antineoplastic activity, i.e., activity for inhibiting the growth of malignant tumors. More specifically it relates to compounds of the class 2,3-bis(aziridinyl)-1,4-naphthoquinone sulfonate derivatives,

BACKGROUND OF THE INVENTION .beta.-lapachone (3,4-dihydro-2,2-dimethyl-2H-naphtho[1,2-b]pyran-5,6-dione), a quinone, is derived from lapachol (a naphthoquinone) which can be isolated from the lapacho tree (Tabebuia avellanedae), a member of the catalpa family (Bignoniaceae). Lapachol and

BACKGROUND OF THE INVENTION .beta.-lapachone (3,4-dihydro-2,2-dimethyl-2H-naphtho[1,2-b]pyran-5,6-dione), a quinone, is derived from lapachol (a naphthoquinone) which can be isolated from the lapacho tree (Tabebuia avellanedae), a member of the catalpa family (Bignoniaceae). Lapachol and

FIELD OF THE INVENTION The present invention relates to novel dye-sulfenate compounds, and to phototherapeutic procedures using these compounds. BACKGROUND OF THE INVENTION The use of visible and near-infrared (NIR) light in clinical practice is growing rapidly. Compounds absorbing or emitting in

INCORPORATION-BY-REFERENCE OF MATERIAL SUBMITTED ELECTRONICALLY The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Mar. 3, 2017, is named P12589-05_ST25.txt and

BACKGROUND OF THE INVENTION Development of safe and effective agents for reducing the risk of cancer and other chronic diseases is a high priority of contemporary medicine. Implementation of strategies for chemoprevention/chemoprotection is beset with many problems. In the economically developed

FIELD OF THE INVENTION The present invention relates in general to anticancer agents, and more specifically to synthetic analogs of deoxypreussomerin, palmarumycin CP.sub.1 and related naphthoquinone spiroketals, which exhibit antimitotic activity. BACKGROUND OF THE INVENTION The cell cycle consists